At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 17 enrolled
Drug / intervention
Gabapentindrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Medication Development for Opioid and Alcohol Abuse: Laboratory Study in Humans.
In Brief
A Phase 2 clinical trial evaluating Gabapentin for Opioid-use Disorder and Alcohol Use Disorder. Completed, enrolled 17 participants across 1 site.
Detailed Summary
The present proposal will evaluate the ability of gabapentin maintenance to reduce the abuse liability of alcohol, oxycodone, and alcohol in combination with oxycodone in participants with both Opioid Use Disorder and Alcohol Use Disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOpioid-use Disorder, Alcohol Use Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedJul 2017
Enrollment StartAug 2017
Primary CompletionJun 2021
Study CompletionDec 2021
TodayJul 2026
First PostedJul 2, 2017
Enrollment StartAug 1, 2017
Primary CompletionJun 30, 2021
Study CompletionDec 30, 2021
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 9 years ago
Interventions
Gabapentindrug
Maintenance medication under investigation for its ability to alter the subjective and reinforcing effects of experimenter-administered doses of oxycodone and alcohol.